Evidence map›Paper›PMID 42194578›Full record

ArticleJournal of clinical medicine2026

The Royal Marsden Hospital Score Independently Predicts Overall Survival in Patients with De Novo Metastatic Renal Cell Carcinoma Treated with First-Line Tyrosine Kinase Inhibitors: A Multicenter Retrospective Analysis.

Tolga Doğan, Semra Taş, Taliha Güçlü Kantar, İrfan Karahan, Atike Gökçen Demiray, Musa Barış Aykan, Burcu Yapar Taşköylü, Melek Özdemir, Arzu Yaren, Nuri Karadurmuş and 1 more

Abstract read
In one paragraph

Article in Journal of clinical medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Tolga DoğanDepartment of Medical Oncology, Denizli State Hospital, 20010 Denizli, Türkiye.ORCID 0000-0003-1281-942X
Semra TaşDepartment of Medical Oncology, Faculty of Medicine, Pamukkale University, 20070 Denizli, Türkiye.
Taliha Güçlü KantarDepartment of Medical Oncology, Denizli State Hospital, 20010 Denizli, Türkiye.ORCID 0000-0002-7836-4272
İrfan KarahanDepartment of Medical Oncology, Zonguldak Bülent Ecevit University, 67100 Zonguldak, Türkiye.ORCID 0000-0003-4669-1751
Atike Gökçen DemirayDepartment of Medical Oncology, Faculty of Medicine, Pamukkale University, 20070 Denizli, Türkiye.
Musa Barış AykanDepartment of Medical Oncology, Gülhane Training and Research Hospital, University of Health Sciences, 06010 Ankara, Türkiye.ORCID 0000-0001-7538-9119
Burcu Yapar TaşköylüDepartment of Medical Oncology, Faculty of Medicine, Pamukkale University, 20070 Denizli, Türkiye.
Melek ÖzdemirDepartment of Medical Oncology, Denizli State Hospital, 20010 Denizli, Türkiye.
Arzu YarenDepartment of Medical Oncology, Faculty of Medicine, Pamukkale University, 20070 Denizli, Türkiye.
Nuri KaradurmuşDepartment of Medical Oncology, Gülhane Training and Research Hospital, University of Health Sciences, 06010 Ankara, Türkiye.
Gamze Gököz DoğuDepartment of Medical Oncology, Faculty of Medicine, Pamukkale University, 20070 Denizli, Türkiye.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

IMDCmetastatic renal cell carcinomaoverall survivalprognostic modelRMH scoretyrosine kinase inhibitors

Identifiers

PMID42194578
PMCPMC13207480

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.